New eczema cream trial aims to soothe itchy skin
NCT ID NCT07438509
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a medicated cream called crisaborole works better than a placebo cream for people with mild to moderate eczema. About 270 people aged 12 to 50 will apply the cream twice daily for four weeks. The goal is to see if the cream can clear or nearly clear the eczema rash.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Crisaborole 2% cream
- What this could lead to
- If it works, this could provide a new, locally tested treatment option for mild to moderate eczema, helping clear skin and reduce itching.
- What could go wrong
- This is a Phase 4 trial, so the drug is already approved, but it may not work better than placebo in this specific population. Side effects like skin irritation are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 270 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
12 to 50 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 12 to 50 years * Clinically diagnosed mild to moderate atopic dermatitis (ISGA score 2 or 3) * Willing and able to apply topical medication twice daily for four weeks * Able to provide written informed consent (parental consent for participants under 18 years) Exclusion Criteria: * Severe atopic dermatitis (ISGA score 4) * Use of systemic corticosteroids, immunosuppressants, or antibiotics within the past two weeks * Known hypersensitivity to crisaborole or any component of the formulation * Pregnant or lactating women * Presence of other significant dermatological conditions that may interfere with evaluation (e.g., psoriasis, scabies) * Immunocompromised status (e.g., HIV infection, organ transplant recipient)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atopic dermatitis (AD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.